Research and developmentof regenerative medicine products, such as iPS cells, and optimization of manufacturing and quality processes and supply systems. Supporting physician-initiated clinical trials of iPS cell-derived cardiomyocyte sheets conducted by Osaka University.                        

Strengths in culture and analysis technologies essential for development and commercialization of regenerative medicine products using iPS cell-derived cardiomyocytes based on research by Prof. Yoshiki Sawa (Osaka University)